LBA3 Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65/KEYNOTE-B96 study

N. Colombo, E. Zsiros, A. Sebastianelli, M. Bidzinski, Cristián Araneda, Emad Matanes, K. Hasegawa, F. Kose, M.E. Magallanes Maciel, Rebecca Herbertson, S. Ananda, Judith R. Kroep, Andréia Cristina de Melo, P.R. Debruyne, Jong‐Woo Kim, X. Peng, K.U. Yamada, A.M. Bogusz, T. De La Motte Rouge, X. Wu